



## 2016 Modafinil (generic Provigil®) prior authorization request Page 1 of 2

(You must complete both pages.)

Please fax completed form to: 1-800-639-9158 For urgent requests, please call: 1-800-551-2694

Patient information	Prescriber information						
Patient name		Today's date	Physician sp	Physician specialty			
Patient insurance ID number		Physician name		NPI/DEA number			
Patient address, city, state, ZIP		Physician address, city, state, ZIP					
Patient home telephone number	M.D. office telephone number						
Gender  Male Female	Patient date of birth	M.D. office fax number					
Diagnosis and medical information	on .						
Medication requested			Frequency				
☐ Modafinil: ☐ 100 m	g tablet 🔲 200 mg tablet						
New prescription OR date therap	y initiated	Quantity	Day supply	Expected length of therapy			
	n any tier of the plan's formulary v		tive for the enrolled	e as the requested formulary			
drug and/or would likely have adverse effects for the enrollee.  2. Yes No Is the prescriber board certified as a sleep specialist, ear, nose and throat, neurologist or pulmonologist or has obtained a consult from a board certified sleep specialist? If NO, complete section below:  Please complete this section below only if your patient does not meet the standard requirements listed above.  Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)							
	tment of a confirmed diagnosis of						





## Page 2 of 2

4.	☐ Yes	No For treatment of excessive daytime sleepiness associated with obstructive sleep apnea (OSA). Does patient have ALL of the following? If NO, complete section below:							
			andard Diagnostic Nocturnal Polysomnography (NPSG) has confirmed the diagnosis of OSA and meets ICSD or DSM nostic criteria.						
		Daytime t	sylvime fatigue is significantly impacting, impairing, or compromising the patient's ability to function normally.  escribing physician has established a patient care plan to treat the cause of OSA in conjunction with treating the daily fatigue.						
				·	•	• • •			
	Please e should in	Please complete this section below only if your patient does not meet the standard requirements listed above.  Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement hould include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)							
	mormat	ion that is	incomplete of illegible will dela	y the review process.)					
5.	☐ Yes ☐ No The following quantity limits (QL) apply to modafinil: 100mg QL 30 units per 30 days, 200mg QL 60 units per 30 days (State of Illinois QL 30 units per 30 days). Does the patient require higher dosage (quantity limit exception)?								
				uested: per 30 days		·			
	☐ The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.								
	The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee, and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.								
6.	☐ Pleas	se list all	medications the patient has t	ried specific to the diagnosis and	specify below.				
	CURREI	NT/PAST	MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC	OUTCOME			
7.	☐ Othe	r support	ing information						
	*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.								
а	nd that d	ocumenta	tion supporting this information	necessary for this patient. I further at is available for review if requested by	y the health plan:	sponsor, or, if applicable, a state or			
n	naterial to	a claim u	Itimately paid by the United Sta	erson who knowingly makes or cause ates government or any state governr	ment may be subj	ect to civil penalties and treble			
damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.									
_		r signatu	*	-		Date			

Visit our websites at www.firsthealthpartd.com, www.chcadvantra.com, www.summithealthplan.com and www.vistahealthplan.com

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-551-2694.